Celecoxib/amlodipine besylate: Additional Phase III data

Additional data from a double-blind, placebo-controlled, U.K. Phase III trial in 152 patients with hypertension showed that once-daily oral 200 mg celecoxib/10 mg amlodipine besylate for 2 weeks reduc...